LAURUS LABS

LAURUS LABS

KEENLY FOCUSED ON GROWTH

Laurus Labs has showcased impressive growth in the custom synthesis and FDF segments, capitalising on the rising demand for CDMO services. Geopolitical developments, such as the U.S. Biosecure Act aimed at reducing dependence on Chinese pharmaceutical suppliers, have positioned Indian CDMO players, including Laurus Labs, to capture new opportunities. For long-term investors, the company holds potential 

Rate this article:
3.8

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2025

Multibaggers31-Mar, 2025

Bonus and Spilt Shares31-Mar, 2025

Penny Stocks31-Mar, 2025

Multibaggers31-Mar, 2025

Knowledge

Knowledge28-Mar, 2025

General22-Mar, 2025

MF14-Mar, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR